Cardiac magnetic resonance T1 mapping pre and post contrast in heart transplant patients with clinical antibody-mediated rejection: a preliminary experience
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1532-429X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cardiac magnetic resonance T1 mapping pre and post contrast in heart transplant patients with clinical antibody-mediated rejection: a preliminary experience ; volume:16 ; number:1 ; day:16 ; month:1 ; year:2014 ; pages:1 ; date:1.2014
Journal of cardiovascular magnetic resonance ; 16, Heft 1 (16.1.2014), 1, 1.2014
- Creator
-
Vermes, Emmanuelle
- Contributor
-
Pucheux, Julien
Delhommais, Anne
Alison, Daniel
Brunereau, Laurent
SpringerLink (Online service)
- DOI
-
10.1186/1532-429X-16-S1-P100
- URN
-
urn:nbn:de:1111-2016032314004
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
2025-08-14T10:56:18+0200
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Vermes, Emmanuelle
- Pucheux, Julien
- Delhommais, Anne
- Alison, Daniel
- Brunereau, Laurent
- SpringerLink (Online service)
Other Objects (12)
HLA antibody-mediated pathways in human endothelial cells and transplant rejection
Late antibody-mediated rejection in a kidney transplant recipient: COVID 19 induced?
Treatment of chronic active antibody-mediated rejection in renal transplant recipients – a single center retrospective study
Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial
Misidentification of preformed anti-HLA-DP antibodies leads to antibody-mediated kidney transplant rejection: a case report
Antibody-mediated rejection of arterialised venous allografts is inhibited by immunosuppression in rats : Antibody-mediated rejection of arterialised venousallografts is inhibited by immunosuppression in rats
Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation
Risk of cellular or antibody-mediated rejection in pediatric kidney transplant recipients with BK polyomavirus replication—an international CERTAIN registry study
Native T1 mapping detects both acute clinical rejection and graft dysfunction in pediatric heart transplant patients
Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
Disruption of Tfh:B Cell Interactions Prevents Antibody-Mediated Rejection in a Kidney Transplant Model in Rats: Impact of Calcineurin Inhibitor Dose
Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design
HLA antibody-mediated pathways in human endothelial cells and transplant rejection
Late antibody-mediated rejection in a kidney transplant recipient: COVID 19 induced?
Treatment of chronic active antibody-mediated rejection in renal transplant recipients – a single center retrospective study
Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial
Misidentification of preformed anti-HLA-DP antibodies leads to antibody-mediated kidney transplant rejection: a case report
Antibody-mediated rejection of arterialised venous allografts is inhibited by immunosuppression in rats : Antibody-mediated rejection of arterialised venousallografts is inhibited by immunosuppression in rats
Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation
Risk of cellular or antibody-mediated rejection in pediatric kidney transplant recipients with BK polyomavirus replication—an international CERTAIN registry study
Native T1 mapping detects both acute clinical rejection and graft dysfunction in pediatric heart transplant patients
Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
Disruption of Tfh:B Cell Interactions Prevents Antibody-Mediated Rejection in a Kidney Transplant Model in Rats: Impact of Calcineurin Inhibitor Dose
Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design
HLA antibody-mediated pathways in human endothelial cells and transplant rejection
Late antibody-mediated rejection in a kidney transplant recipient: COVID 19 induced?
Treatment of chronic active antibody-mediated rejection in renal transplant recipients – a single center retrospective study
Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial
Misidentification of preformed anti-HLA-DP antibodies leads to antibody-mediated kidney transplant rejection: a case report
Antibody-mediated rejection of arterialised venous allografts is inhibited by immunosuppression in rats : Antibody-mediated rejection of arterialised venousallografts is inhibited by immunosuppression in rats
Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation
Risk of cellular or antibody-mediated rejection in pediatric kidney transplant recipients with BK polyomavirus replication—an international CERTAIN registry study
Native T1 mapping detects both acute clinical rejection and graft dysfunction in pediatric heart transplant patients
Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
Disruption of Tfh:B Cell Interactions Prevents Antibody-Mediated Rejection in a Kidney Transplant Model in Rats: Impact of Calcineurin Inhibitor Dose